Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...

If you have type 2 diabetes, your doctor may suggest Bydureon BCise (exenatide extended-release) as a treatment option. Along with other factors, you may have questions about possible side effects of ...

SAN DIEGO and DUBLIN, Ireland - January 27, 2012 /PRNewswire/ - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration ...

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS ...

Eli Lilly and Company together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on ...

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...

The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...